Yellow Ribbon Tree
appen grocery
Northside Oral Surgery
appen dec 2010

STUDY: Targeting inflammation to treat depression


September 05, 2012


ATLANTA -- Researchers at Emory University have found that a medication that inhibits inflammation may offer new hope for people with difficult-to-treat depression. The study was published Sept. 3 in Online First Archives of General Psychiatry.

"Inflammation is the body's natural response to infection or wounding," says Andrew H. Miller, MD, senior author for the study and professor of Psychiatry and Behavioral Sciences at Emory University School of Medicine. "However, when prolonged or excessive, inflammation can damage many parts of the body, including the brain."

Prior studies have suggested that depressed people with evidence of high inflammation are less likely to respond to traditional treatments for the disorder, including anti-depressant medications and psychotherapy. This study was designed to see whether blocking inflammation would be a useful treatment for either a wide range of people with difficult-to-treat depression or only those with high levels of inflammation.

The study employed infliximab, one of the new biologic drugs used to treat autoimmune and inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. A biologic drug copies the effects of substances naturally made by the body's immune system. In this case, the drug was an antibody that blocks tumor necrosis factor (TNF), a key molecule in inflammation that has been shown to be elevated in some depressed individuals.

Study participants all had major depression and were moderately resistant to conventional antidepressant treatment. Each participant was assigned either to infliximab or to a non-active placebo treatment.

When investigators looked at the results for the group as a whole, no significant differences were found in the improvement of depression symptoms between the drug and placebo groups. However, when the subjects with high inflammation were examined separately, they exhibited a much better response to infliximab than to placebo.

"The prediction of an antidepressant response using a simple blood test is one of the holy grails in psychiatry," says Miller. "This is especially important because the blood test not only measured what we think is at the root cause of depression in these patients, but also is the target of the drug."

Inflammation in this study was measured using a simple blood test that is readily available in most clinics and hospitals and measures C-reactive protein or CRP. The higher the CRP, the higher the inflammation, and the higher the likelihood of responding to the drug.

"This is the first successful application of a biologic therapy to depression," says Charles L. Raison, MD, first author of the study. "The study opens the door to a host of new approaches that target the immune system to treat psychiatric diseases." Raison, formerly at Emory, is now associate professor in the Department of Psychiatry at the University of Arizona College of Medicine Tucson.

printPrint
emailEmail Link
CommentFeedback
shareShare

Tags: Community & Outreach

  1. report print email
    depression
    September 06, 2012 | 07:17 AM

    In a study published earlier this year, transcranial direct current stimulation (tDCS)reduced depression scores 50% in patients with treatment-resistant depression. Cognitive function improved with the initial 20-minute treatment and depression lessened within a week. tDCS uses tiny amounts of electricity from a stimulator powered by a 9 volt battery via sponge electrodes. tDCS also demonstrated reduction of neuroinflammtion. tDCS is easy to do, has no side effects, can be done by the patient at home and the lifetime cost is less than the cost of an antidepressant for a year. 40% of depressed patients do not respond to antidepressants whose side effects include weight gain and decreased libido. Infection is the most common side effect of infleximab. tDCS also provides relief for chronic pain, including migraine, fibromyalgia and complex regional pain.

    James Fugedy
    Marietta
READER COMMENTS Submission
When posting feedback please be respectful. Be nice. :
* required value
Your Name*

Town*

Email (not shown on website)*

Subject*

Comment*

Verification*
Identify the animal




Coldwell Banker
Biz Post
RECENT CLASSIFIEDS
Part-time

P.T. Upscale House Cleaner 11.00 hr.

August 19, 2014 | 09:56 PM
14 year old company has an »
Furniture

Lane Dining Set

August 19, 2014 | 08:51 PM
Solid wood Lane dining set »
Furniture

Chair - A steal at this price!

August 19, 2014 | 06:10 PM
Nice down overstuffed chair. »

Georgetown Pediatrics
appen dec 2010 Duplicate